- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc stock price live, this page displays NASDAQ DNLI stock exchange data. View the DNLI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Denali Therapeutics Inc real time stock price chart below.
What Is the Denali Therapeutics Inc Stock Price Today?
The Denali Therapeutics Inc stock price today is 24.40.
What Is the Stock Symbol for Denali Therapeutics Inc?
The stock symbol for Denali Therapeutics Inc is "DNLI."
What Stock Exchange Does Denali Therapeutics Inc Trade On?
Denali Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Denali Therapeutics Inc a Good Stock to Buy?
Determining whether Denali Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNLI quote. (ISIN: US24823R1059)
What Is the Denali Therapeutics Inc Stock Price Today?
The Denali Therapeutics Inc stock price today is 24.40.
What Is the Stock Symbol for Denali Therapeutics Inc?
The stock symbol for Denali Therapeutics Inc is "DNLI."
What Stock Exchange Does Denali Therapeutics Inc Trade On?
Denali Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Denali Therapeutics Inc a Good Stock to Buy?
Determining whether Denali Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNLI quote. (ISIN: US24823R1059)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.12
24.62
52 wk Range
12.58
27.30
DNLI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.1224.62
52 wk Range
12.5827.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DNLI Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
35.44
Upside
+45.24%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
11 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
19 Buy
1 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.44
(+45.24% Upside)
Denali Therapeutics Inc Earnings Call Summary for Q2/2026
- Denali posted Q2 revenue of $3.6M vs. $11.94M expected, missing by 70%, with adjusted loss of $0.68/share vs. $0.64 forecast.
- AVLAYAH generated $3.6M in first full commercial quarter; company secured coverage for 50%+ of covered lives and guided Q3 revenue to $10M-$12M.
- Cash position stands at $940M, bolstered to $1.1B+ after $195M priority review voucher sale, funding commercial launch and pipeline.
- Phase III COMPASS study runs through 2027 for label expansion; Alzheimer's programs DNL628 and DNL921 expected to report data in 2027.
- Stock rose 1.5% after-hours to $25.10 as investors focused on launch trajectory over revenue miss; shares up 72% over past year.
Last Updated: 08/07/2026, 06:00 AM
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.68 / -0.64
Revenue / Forecast
3.6M / 11.94M
Compare DNLI to Peers and Sector
Metrics to compare | DNLI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDNLIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.6x | −1.9x | −0.4x | |
PEG Ratio | 8.45 | −0.03 | 0.00 | |
Price/Book | 4.7x | 1.5x | 2.6x | |
Price / LTM Sales | 1,082.2x | 74.1x | 3.1x | |
Upside (Analyst Target) | 41.0% | 198.0% | 47.8% | |
Fair Value Upside | Unlock | −3.6% | 6.2% | Unlock |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Denali Therapeutics (DNLI) Stock Price Today?
The Denali Therapeutics stock price today is 24.40 USD.
What Stock Exchange Does Denali Therapeutics Trade On?
Denali Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Denali Therapeutics?
The stock symbol for Denali Therapeutics is "DNLI."
What Is the Denali Therapeutics Market Cap?
As of today, Denali Therapeutics market cap is 3.97B USD.
What Is Denali Therapeutics's Earnings Per Share (TTM)?
The Denali Therapeutics EPS (TTM) is -2.83.
When Is the Next Denali Therapeutics Earnings Date?
Denali Therapeutics will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is DNLI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Denali Therapeutics Stock Split?
Denali Therapeutics has split 0 times.
How Many Employees Does Denali Therapeutics Have?
Denali Therapeutics has 503 employees.
What is the current trading status of Denali Therapeutics (DNLI)?
As of Aug 15, 2026, Denali Therapeutics (DNLI) is trading at a price of 24.40 USD, with a previous close of 24.82 USD. The stock has fluctuated within a day range of 24.12 USD to 24.62 USD, while its 52-week range spans from 12.58 USD to 27.30 USD.
What Is Denali Therapeutics (DNLI) Price Target According to Analysts?
The average 12-month price target for Denali Therapeutics is 35.44 USD, with a high estimate of 42 USD and a low estimate of 27 USD. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.24% Upside potential.
What Is the DNLI Premarket Price?
DNLI's last pre-market stock price is 24.61 USD. The pre-market share volume is 2,720.00, and the stock has decreased by -0.21, or -0.85%.
What Is the DNLI After Hours Price?
DNLI's last after hours stock price is 24.56 USD, the stock has decreased by 0.16, or 0.66%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.